Incyte Q3 Loss/Shr Narrows - Quick Facts

(RTTNews) - Incyte Corp. (INCY) reported third-quarter 2013 net loss of $22.04 million, or $0.14 per share, as compared with a $21.71 million, or $0.17 per share loss, for the same period in 2012. On average, 13 analysts polled by Thomson Reuters expected loss per share of $0.13 for the quarter. Analysts' estimates typically exclude one-time items.

Total revenues for the quarter grew to $85.1 million, from $60.5 million in the comparable period in 2012. Analysts estimated revenues of $81.37 million for the recent period.

The company also described: positive top-line results of its Phase II trial (RECAP) of ruxolitinib in patients with refractory metastatic pancreatic cancer; positive Phase II proof-of-concept data recently presented at key scientific meetings for its lead JAK1 inhibitor, INCB39110; and progress for several of its other key clinical programs.